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Abstract
Background: Individual clinical trials and cohort studies are a useful source of data, often under-utilised once a
study has ended. Pooling data from multiple sources could increase sample sizes and allow for further investigation
of treatment effects; even if the original trial did not meet its primary goals. Through the MASTERPLANS
(MAximizing Sle ThERapeutic PotentiaL by Application of Novel and Stratified approaches) national consortium,
focused on Systemic Lupus Erythematosus (SLE), we have gained valuable real-world experiences in aligning,
harmonising and combining data from multiple studies and trials, specifically where standards for data capture,
representation and documentation, were not used or were unavailable. This was not without challenges arising
both from the inherent complexity of the disease and from differences in the way data were captured and
represented across different studies.
Main body: Data were, unavoidably, aligned by hand, matching up equivalent or similar patient variables across
the different studies. Heterogeneity-related issues were tackled and data were cleaned, organised and combined,
resulting in a single large dataset ready for analysis. Overcoming these hurdles, often seen in large-scale data
harmonization and integration endeavours of legacy datasets, was made possible within a realistic timescale and
limited resource by focusing on specific research questions driven by the aims of MASTERPLANS. Here we describe
our experiences tackling the complexities in the integration of large, diverse datasets, and the lessons learned.
Conclusions: Harmonising data across studies can be complex, and time and resource consuming. The work
carried out here highlights the importance of using standards for data capture, recording, and representation, to
facilitate both the integration of large datasets and comparison between studies. Where standards are not
implemented at the source harmonisation is still possible by taking a flexible approach, with systematic preparation,
and a focus on specific research questions.
Keywords: Data integration, Data harmonisation, Clinical trials, Lupus, Pooled analysis
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: nophar.geifman@manchester.ac.uk
1Centre for Health Informatics, Vaughan Housue, Portsmouth St., The
University of Manchester, Manchester M13 9GB, UK
4The Manchester Molecular Pathology Innovation Centre, The University of
Manchester, Manchester, UK
Full list of author information is available at the end of the article
Sueur et al. BMC Medical Research Methodology          (2020) 20:164 
https://doi.org/10.1186/s12874-020-01057-0
Background
SLE is a chronic autoimmune disease, affecting different
body organs, which presents with a range of symptoms
and clinical manifestations. Whilst several therapies with
differing modes of action are currently in use, individual
response varies and overall, response rates are only 40–
60% to any given treatment. MASTERPLANS, a national
consortium, endeavours to improve on the current trial
and error approach employed in tailoring of care, by tak-
ing a precision medicine approach; improving care for
patients by identifying groups who respond well to par-
ticular therapies, and the factors that may predict re-
sponse to therapy.
MASTERPLANS has gained access to a wealth of data,
from a range of past clinical trials and patient cohort
studies; several of which have failed to demonstrate effi-
cacy of the drug investigated, when compared to stand-
ard of care or placebo [1, 2]. Despite the lack of detected
treatment effects, data from these studies could still pro-
vide a valuable source of information. Pooling of
patient-level data can increase sample sizes and provide
new opportunities for analysis, while various statistical
approaches can be employed to handle potential study-
specific effects. Framing new research questions around
groups of patients combined across studies could enable
both better understanding of treatment effects, and of
patient characteristics that differ between these groups.
Main text
Accomplishing data harmonisation
Legacy data can be extremely useful, however harmonis-
ing and combining large amounts of data from disparate
datasets is not always straightforward [3–5]. Data inte-
gration would be made easier if data standards were
consistently applied at the source. The Clinical Data
Interchange Standards Consortium provides standards
for data collection, capture, and representation, to im-
prove accessibility, interoperability, and reusability of
data for better clarity in clinical research [6]. Several dif-
ferent frameworks and guidelines have also been devel-
oped to assist with tackling issues related to data
integration across different studies [7–11]. Other initia-
tives have focused on developing therapeutic-area spe-
cific data standards that could better enable data
integration; such as in Polycystic Kidney Disease [12], as
well as for over 30 other disease areas [6]. While using
these is clearly the way forward for improving integrative
research that relies on several data resources, many data-
sets, particularly legacy data, have not followed such
guidelines or applied standards. Projects that want to in-
tegrate and use these data are then faced with the bur-
den of aligning to standards; this is not always planned
for in advance or resources may be limited. Prospective
alignment of datasets, without the availability of
standards, is labour-intensive and often impossible to
achieve perfectly. In such cases, little practical guidance,
taken from real case experiences, is available to those
undertaking this process, with few, if any details given
where similar work has been carried out. To begin with,
understanding the content of large datasets and then
aligning variables to a common data model, based on
similarity is extremely time-consuming. This process of
alignment is undertaken manually due to nuanced com-
plexities that require human interpretation and know-
ledge with regards to differences in the way data is
captured and identified within the different studies being
integrated. The successful process requires good docu-
mentation and comprehensive data dictionaries, explain-
ing the content of table fields and outlining calculations
that were made. Furthermore, the complexity of the in-
tegration problem only becomes apparent once align-
ment has taken place. In some medical fields, for
example: cancer, outcome measures are well-defined
clinically and recorded in a standard universal way.
However this is not the case in many more complex and
multi-faceted diseases, such as lupus. Differences in the
response measures taken across studies can affect how
response (e.g. remission and low disease activity) can be
defined in the integrated set; responders may be defined
using a response measure in one study that was not col-
lected in another study. Projects such as MASTER-
PLANS must therefore tackle this additional level of
complexity that is inherent in the study of conditions
such as SLE.
We propose that prospective alignments of unstandar-
dised data is achievable with limited resource when spe-
cific research questions are used to direct which data are
to be integrated across studies.
Here we describe our own experience applying this ap-
proach in the integration of data from four lupus studies.
These studies included i) The Aspreva Lupus Manage-
ment Study (ALMS) study, a prospective randomized
trial aimed at assessing the efficacy and safety of long
term mycophenolate mofetil (MMF) compared to azathi-
oprine and cyclophosphamide in patients with SLE [13];
ii) The LUNAR randomized, placebo-controlled trail
evaluating the efficacy and safety of rituximab [2]; iii)
EXPLORER, a second randomized, placebo-controlled of
rituximab with background treatment distributed among
azathioprine, mycophenolate mofetil and methotrexate
[1]; and iv) British Isles Lupus Assessment Group Bio-
logics Register (BILAG BR) a national patient registry
looking at the safety and effectiveness of biologic and
bio-similar treatment for SLE [14].
In order to carry out analyses on groups of patients
across more than one study, relevant and overlapping
variables were extracted, harmonised and combined into
common tables, taking a common data model approach.
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To simplify and make this laborious process more effi-
cient, only variables likely to be relevant to answering
specific, predefined research questions regarding treat-
ment effects and patient characteristics were extracted,
so that the amount of data to be handled was kept to a
minimum. Variable choice was driven by research ques-
tions related to the MASTERPLANS project plan.
Existing documentation detailing the data tables and
available variables was used to identify relevant and simi-
lar variables from each study and to ascertain which ta-
bles from each dataset should be extracted.
Unfortunately, the different studies did not use similar
data coding standards, making data extraction more
complex. These raw data tables, containing variables of
interest, underwent initial cleaning, removal of duplicate
rows and superfluous variables. Each of these files were
read into Matlab and organised to reflect the content of
the data and structure of the tables. Separate structures
were thereby created for demographics, visit variables,
study drug variables, use of steroids, response variables
and lab chemistry variables. To integrate across studies,
the variables that contained the same or similar informa-
tion from each study were identified manually and
assigned to the same column in merged data-frame.
Each variable was then extracted from the raw data ta-
bles for each study and assigned to the correct column,
placing the data for each subsequent study sequentially
in the same column. These data were then harmonised
and cleaned further.
Lengthy processes were carried out to integrate and
harmonise the data, so that each trial contained compar-
able information that could be analysed together (Fig. 1).
The general procedure outlined here, can be used as a
more generalised guide for how to carry out similar
work in the future. We encountered and tackled several
issues around data heterogeneity. These could be cate-
gorised into types: (i) syntactical heterogeneity, where
the meaning of the data captured is the same across
sources, but the words used to capture the information
are different between different datasets; (ii) content het-
erogeneity (capture), where a whole variable is captured
in one study and not in another; (iii) content heterogen-
eity (granularity); where, for example in ethnicity, some
datasets include more categories and subsets than
others, or where visit time is captured as sequential visit
numbers (i.e. visit 1, visit 2 etc) in one study but as time
from baseline (in days, weeks, or months) in another;
(iv) format heterogeneity (variable) where the same in-
formation, for example dates, is captured in different
formats; and (v) format heterogeneity (dataset/table),
where, for example, a variable is captured in a single row
per patient across many columns in one dataset (wide
format), but in many rows per patient and in one col-
umn in another dataset (long format). In addition,
Fig. 1 Summary of the data flow from individual datasets to final integrated, harmonised table, including examples of the changes made to
the data
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further steps were taken to keep only those patients who
had complete and accurate information. For example,
rows with missing or mistyped dates were removed, pa-
tients were excluded if they were missing key informa-
tion (e.g. treatment, follow up visits, British Isles Lupus
Activity Group - BILAG response measures) and pa-
tients were excluded if they were not on their first bio-
logic treatment. One limitation of this approach is the
inevitable loss of information either due to differences in
granularity or data capture; another is that the final pa-
tient group may suffer from selection biases. For ex-
ample, patients on a second biologic may have more
severe and/or more refractory disease and so excluding
this group changes the attributes of the patients who are
being analysed. Furthermore, excluding patients and
rows of data based on missingness reduces the sample
sizes and again, introduces potential biases.
Conclusions
Our integration and harmonisation across SLE studies
took a considerable length of time and is very specific to
the data provided to MASTERPLANS. A more flexible,
automated approach would significantly benefit future
similar projects. Many of the steps carried out to gener-
ate the harmonised data resource required manual
evaluation and examination of the data by an experi-
enced data analyst; this is a tremendous waste of re-
source that is not uncommon in such projects. The
work carried out here highlights the importance of
standardisation, particularly regarding validated mea-
sures of disease response across both clinical trials and
patient registries, at the clinical level. Application of
standards for recording data at the source, measures that
need including, and the format of variables, will facilitate
both the integration of large datasets and comparison
between studies. Significant efforts are being made to
implement standards, such as the Fast Healthcare Inter-
operability Resources (FHIR) [8], across healthcare and
medical research; however many data resources, espe-
cially legacy datasets, remain unstandardised. Where
standards are not implemented at the source, reality dic-
tates having to make a compromise in setting the ap-
proach; we argue that this can be made easier when
specific research questions are used to direct which data
are to be integrated across studies.
Similar integration work would benefit from the input
of a data management specialist at the earliest stages in
the conception of a project or trial. This would also
allow for standardisation of the resulting integrated data-
set, benefiting future investigations.
Despite the limitations, this work provides a useful,
generalised procedure to address the known complex-
ities in the integration of large datasets. Three key ap-
proaches were vital to the success of this work.
Systematic preparation regarding the data alignment be-
fore starting to integrate was essential. A flexible ap-
proach, enabling the addition of new variables and new
datasets, meant that the resulting output could be up-
dated easily to answer new research questions if re-
quired. Finally, a focus on specific, well-defined, research
questions meant that the dataset size remained manage-
able and was tailored by design for its intended use.
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